Hwang to Sue U.S. Collaborator Over Stem Cell Patent
By Chosun Ilbo,
Chosun Ilbo
| 02. 14. 2006
Lawyers for the disgraced cloning scientist Hwang Woo-suk on Monday decided to take legal action against Hwang_s one-time collaborator Prof. Gerald Schatten, who is insisting on his right to a stem-cell technology patent. Schatten, of the University of Pittsburgh, is a co-author of Hwang_s discredited 2005 Science paper on patient-specific stem cells.
Hwang_s lawyers asked Seoul National University, to which Hwang transferred his right to apply for stem-cell related patents, to return the right to the scientist.
They said SNU was attempting to cancel the patent application since Hwang_s research results were fabricated, but Schatten, _who has done nothing to create stem cells,_ had no such compunction and was trying to make the patents for related technology his own. Their plan is to take legal action against Schatten once the university returns the rights.
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...
